Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19

References

• Akacha, M., Branson, J., Bretz, F., Dharan, B., Gallo, P., Gathmann, I., Hemmings, R., Jones, J., Xi, D., and Zuber, E. (2020), “Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1788984.
   PubMed Web of Science ®Google Scholar
• Allignol, A., Beyersmann, J., and Schmoor, C. (2016), “Statistical Issues in the Analysis of Adverse Events in Time-to-Event Data,” Pharmaceutical Statistics 15, 297–305, DOI: 10.1002/pst.1739.
   PubMed Web of Science ®Google Scholar
• Allison, P. D. (2018), “For Causal Analysis of Competing Risks, Don’t Use Fine & Gray’s Subdistribution Method,” available at https://statisticalhorizons.com/for-causal-analysis-of-competing-risks.
   Google Scholar
• Association of Clinical Research Organizations (2020), “Considerations to Support Clinical Trial Monitoring Oversight During COVID-19,” available at https://www.acrohealth.org/wp-content/uploads/2020/03/ACRO-Statement-on-Monitoring-Oversight-FINAL-3.13.20.pdf.
   Google Scholar
• Bender, R., Beckmann, L., and Lange, S. (2016), “Biometrical Issues in the Analysis of Adverse Events Within the Benefit Assessment of Drugs,” Pharmaceutical Statistics, 15, 292–296, DOI: 10.1002/pst.1740.
   PubMed Web of Science ®Google Scholar
• CDISC (2020), “CDISC Interim User Guide for COVID-19,” available at https://wiki.cdisc.org/display/COVID19/CDISC+Interim+User+Guide+for+COVID-19.
   Google Scholar
• CIOMS Working Groups III and V (1999), “Guidelines for Preparing Core Clinical Safety Information on Drugs,” Council for International Organizations of Medical Sciences, Geneva.
   Google Scholar
• CIOMS Working Group VI (2005), “Management of Safety Information From Clinical Trials,” Council for International Organizations of Medical Sciences, Geneva.
   Google Scholar
• Collins, S. H., and Levenson, M. S. (2020), “Comment on Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1779123.
   PubMed Web of Science ®Google Scholar
• Crowe, B. J., Brueckner, A., Beasley, C., and Kulkarni, P. (2013), “Current Practices, Challenges, and Statistical Issues With Product Safety Labeling,” Statistics in Biopharmaceutical Research, 5, 180–193, DOI: 10.1080/19466315.2013.791640.
   Web of Science ®Google Scholar
• Crowe, B. J., Xia, H. A., Berlin, J. A., Watson, D. J., Shi, H., Lin, S. L., Kuebler, J., Schriver, R. C., Santanello, N. C., Rochester, G., Porter, J. B., Oster, M., Mehrotra, D. V., Li, Z., King, E. C., Harpur, E. S., and Hall, D. B. (2009), “Recommendations for Safety Planning, Data Collection, Evaluation and Reporting During Drug, Biologic and Vaccine Development: A Report of the Safety Planning, Evaluation, and Reporting Team,” Clinical Trials, 6, 430–440. DOI: 10.1177/1740774509344101.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (2020a), “Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic,” available at https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf.
   Google Scholar
• European Medicines Agency (2020b), “Points to Consider on Implications of Coronavirus Disease (COVID-19) on Methodological Aspects of Ongoing Clinical Trials,” Draft.
   Google Scholar
• Foulkes, M. A. (2007), “Safety Assessment Versus Efficacy Assessment,” in Advances in Statistical Methods for the Health Sciences: Applications to Cancer and AIDS Studies, Genome Sequence Analysis, and Survival Analysis, eds. J.-L. Auget, N. Balakrishnan, M. Mesbah, and G. Molenberghs, Birkhäuser Boston, pp. 323–334.
   Google Scholar
• Geskus, R. B. (2016), Data Analysis With Competing Risks and Intermediate States, Boca Raton, FL: CRC Press.
   Google Scholar
• Hemmings, R. (2020), “Under a Black Cloud Glimpsing a Silver Lining: Comment on Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1785931.
   PubMed Web of Science ®Google Scholar
• Hengelbrock, J., Gillhaus, J., Kloss, S., and Leverkus, F. (2016), “Safety Data From Randomized Controlled Trials: Applying Models for Recurrent Events,” Pharmaceutical Statistics, 15, 315–323, DOI: 10.1002/pst.1757.
   PubMed Web of Science ®Google Scholar
• Karvanen, J. (2003), “The Statistical Basis of Laboratory Data Normalization,” Drug Information Journal: DIJ/Drug Information Association, 37, 101–107. DOI: 10.1177/009286150303700112.
   Google Scholar
• Kunz, C. U., Jörgens, S., Bretz, F., Stallard, N., Van Lancker, K., Xi, D., Zohar, S., Gerlinger, C., and Friede, T. (2020), “Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1799857.
   PubMed Web of Science ®Google Scholar
• Ma, H., Ke, C., Jiang, Q., and Snapinn, S. (2015), “Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials,” Therapeutic Innovation & Regulatory Science, 49, 957–965, DOI: 10.1177/2168479015587363.
   PubMed Web of Science ®Google Scholar
• McDermott, M. M., and Newman, A. B. (2020), “Preserving Clinical Trial Integrity During the Coronavirus Pandemic,” JAMA, DOI: 10.1001/jama.2020.4689.
   PubMed Web of Science ®Google Scholar
• MedDRA (2020), “MedDRA Version 23.0 Update 2020,” available at https://www.meddra.org/news-and-events/news/meddra-version-230-update-all-supported-languages-available.
   Google Scholar
• Meyer, R. D., Ratitch, B., Wolbers, M., Marchenko, O., Quan, H., Li, D., Fletcher, C., Li, X., Wright, D., and Shentu, Y. (2020), “Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, DOI: 10.1080/19466315.2020.1779122.
   PubMed Web of Science ®Google Scholar
• Nautiyal, N., Rastogi, R., and Gamperl, H.-J. (2015), “Drug Safety Assessment in Clinical Trials: Concepts and Issues,” International Journal of Pharmaceutical Sciences and Research, 6, 4159.
   Web of Science ®Google Scholar
• PHUSE (2013), “Analyses & Displays Associated With Measures of Central Tendency—Focus on Vital Sign, Electrocardiogram, & Laboratory Analyte Measurements in Phase 2-4 Clinical Trials & Integrated Submission Documents,” Available at https://www.phuse.eu/documents//working-groups/deliverables/analyses-displays-associated-with-measures-of-central-tendancy-version-10-10-oct-13-11816.pdf.
   Google Scholar
• PHUSE (2015), “Analyses and Displays Associated With Outliers or Shifts From Normal to Abnormal: Focus on Vital Signs, Electrocardiogram, and Laboratory Analyte Measurements in Phase 2-4 Clinical Trials and Integrated Summary Documents,” available at https://www.phuse.eu/documents//working-groups/deliverables/analyses-displays-associated-with-outliers-or-shifts-from-normal-to-abnormal-version-10-10-sept-15-11815.pdf.
   Google Scholar
• PHUSE (2017), “Analysis and Displays Associated With Adverse Events: Focus on Adverse Events in Phase 2-4 Clinical Trials and Integrated Summary Documents,” available at https://www.phuse.eu/documents//working-groups/deliverables/adverse-events-white-paper-version-10-03-feb-17-11796-19835.pdf.
   Google Scholar
• PHUSE (2019), “Safety Analytics Workshop Slides,” available at https://www.phuse.eu/documents//working-groups/deliverables/safetyanalyticsworkshop-PHUSEcss2019-21959.pptx.
   Google Scholar
• Proctor, T., and Schumacher, M. (2016), “Analysing Adverse Events by Time-to-Event Models: The CLEOPATRA Study,” Pharmaceutical Statistics, 15, 306–314, DOI: 10.1002/pst.1758.
   PubMed Web of Science ®Google Scholar
• Rosario, L. A., Kropp, T. J., Wilson, S. E., and Cooper, C. K. (2012), “Join FDA/PhUSE Working Groups to Help Harness the Power of Computational Science,” Drug Information Journal, 46, 523–524. DOI: 10.1177/0092861512456839.
   Google Scholar
• Senior, J. R. (2014), “Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges,” Drug Safety, 37, 9–17, DOI: 10.1007/s40264-014-0182-7.
   PubMed Web of Science ®Google Scholar
• Singh, S., and Loke, Y. K. (2012), “Drug Safety Assessment in Clinical Trials: Methodological Challenges and Opportunities,” Trials, 13, 138. DOI: 10.1186/1745-6215-13-138.
   PubMed Web of Science ®Google Scholar
• Stegherr, R., Beyersmann, J., Jehl, V., Rufibach, K., Leverkus, F., Schmoor, C., and Friede, T. (2019), “Survival Analysis for AdVerse Events With VarYing Follow-Up Times (SAVVY): Rationale and Statistical Concept of a Meta-Analytic Study,” arXiv no. 1912.00263.
   Google Scholar
• TransCelerate Biopharma Inc. (2020), “Clinical Study Report Considerations for Studies Disrupted by the COVID-19 Pandemic,” available at http://transceleratebiopharmainc.com/wp-content/uploads/2020/05/TransCelerate_CSR_Considerations-for-Studies-Disrupted-by-the-COVID-19-Pandemic_May2020.pdf.
   Google Scholar
• U.S. Food and Drug Administration (2009), “Guidance for Industry, Drug-Induced Liver Injury: Premarketing Clinical Evaluation,” available at https://www.fda.gov/media/116737/download.
   Google Scholar
• U.S. Food and Drug Administration (2020), “FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards,” available at https://www.fda.gov/media/136238/download.
   Google Scholar
• Unkel, S., Amiri, M., Benda, N., Beyersmann, J., Knoerzer, D., Kupas, K., Langer, F., Leverkus, F., Loos, A., Ose, C., Proctor, T., Schmoor, C., Schwenke, C., Skipka, G., Unnebrink, K., Voss, F., and Friede, T. (2019), “On Estimands and the Analysis of Adverse Events in the Presence of Varying Follow-Up Times Within the Benefit Assessment of Therapies,” Pharmaceutical Statistics, 18, 166–183, DOI: 10.1002/pst.1915.
   PubMed Web of Science ®Google Scholar